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Background. Accurate diagnostic tools to identify patients at risk of cancer therapy-related
cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy,
ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used
for serial assessment of left ventricular (LV) function.
Methods. In this retrospective study, approximate entropy (ApEn), synchrony, entropy,
and standard deviation from the phase histogram (phase SD) were investigated as potential
early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated
from the baseline RNVG phase image for 177 breast cancer patients before commencing car-
diotoxic therapy.
Results. Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of
over 10% to an LVEF below 50% after treatment had commenced. This patient group had a
significantly higher ApEn at baseline to those who maintained a normal LVEF throughout
treatment. Of the parameters investigated, ApEn was superior for predicting the risk of
CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination
between the groups.
Conclusions. The results suggest that RNVG phase analysis using approximate entropy
may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline
LVEF measurement, predicting a subsequent decline in LVEF. (J Nucl Cardiol 2020)
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Abbreviations
CTRCD Cancer therapy-related cardiac
dysfunction
LVEF Left ventricular ejection fraction
RNVG Radionuclide ventriculography
MUGA Multi-gated acquisition study
GLS Global longitudinal strain
LBBB Left bundle branch block
MI Myocardial Infarction
ApEn Approximate entropy
SD Standard deviation
INTRODUCTION
Survival from breast cancer has improved substan-
tially over the last 20 to 30 years due to earlier diagnosis
and advances in treatment with adjuvant radiotherapy
and chemotherapy. However, cardiotoxicity as a result
of this therapy is now the leading cause of morbidity and
mortality for survivors.1,2
Radiotherapy and anthracycline/trastuzumab-based
chemotherapy regimens have been associated with
increased risk of cardiovascular disease.3 Anthracy-
cline-based regimens are associated with the dose-
dependent risk of Type 1 cardiotoxicity and heart
failure, while trastuzumab is generally associated with
reversible Type 2 cardiotoxicity. However, permanent
cardiac dysfunction can occur with both Type 1 and 2
cardiotoxicity, despite intervention.4 The risk of cancer
therapy-related cardiac dysfunction (CTRCD) increases
significantly when trastuzumab is combined with anthra-
cyclines.5 Cardiac monitoring is required for patients
receiving anthracycline/trastuzumab-based treatments,
and currently, this relies on the serial assessment of left
ventricular ejection fraction (LVEF). Each patient will
have a baseline LVEF measurement, then serial LVEF
assessment every 3 months during treatment. The
European Society of Cardiology (ESC) guidelines con-
sider a 10% point decrease of LVEF to below the lower
limit of normal (\ 50%) to be an indicator of cardiotox-
icity and recommend treatment is altered or stopped to
prevent further left ventricular (LV) dysfunction or the
development of symptomatic heart failure.6
One potential limitation of the current guidelines is
that LVEF decline is often a late phenomenon. There-
fore, it would be useful if we can identify sub-clinical
cardiac abnormalities and identify patients who are at
higher risk before treatment starts.
Radionuclide ventriculography (RNVG), also com-
monly known as multi-gated acquisition study (MUGA)
or cardiac blood pool imaging, is a well-established
technique that can reproducibly measure ejection
fraction and is commonly used to assess LV function in
patients undergoing cardiotoxic cancer therapy. Echocar-
diography is also widely used to assess LVEF but is
limited by operator variability and poor reproducibility of
LVEF measurement, especially in patients post mastec-
tomy who have had reconstructive surgery. LV
dyssynchrony can be assessed with a number of imaging
techniques. Recently, there has been increased interest in
echocardiography deformation assessment with global
longitudinal strain (GLS), as an early marker of LV
dysfunction for chemotherapy patients.6
This work aims to determine if phase parameters
applied to baseline RNVG phase images can measure
sub-clinical contraction abnormalities prior to treatment
to predict which patients are at a higher risk of CTRCD.
At present, there are no published studies investigating
RNVG phase parameters as a predictor of CTRCD.
RNVG Phase Images
Phase images, representing the timing of contraction,
can be created from RNVG data to provide additional
information on ventricular function.7,8 The timing of
contraction, relative to the R wave of the ECG, is
obtained from the time-activity curve for each pixel in
the RNVG image to create a phase map; a higher phase
angle indicates delayed contraction within the region. In
a phase image with normal contraction, the pixels within
the LV should all be a similar phase value, representing
synchronous contraction. Regions of dyssynchronous
contraction will appear as delays in the phase images/
histograms. This is illustrated in Figure 1, where the
phase for a patient with an aneurysm, left bundle branch
block (LBBB), or myocardial infarction (MI) has a
distinctly different phase pattern compared to a patient
with normal contraction. This technique can also detect
more subtle phase abnormalities. Phase data from RNVG
images can be quantitatively assessed using the mean and
the standard deviation of the phase histogram.
Approximate Entropy
Various measures have been established to quantify
dyssynchrony. Most parameters previously investigated
are from first-order statistics calculated from the phase
histogram such as phase standard deviation (SD).
O’Connell et al. derived synchrony to describe the
contraction of the left ventricle using the phase and
amplitude data extracted from the region of interest, and
entropy (from Shannon information measure9) as a
measure of randomness of contraction within the ventri-
cle.10 They demonstrated that synchrony and entropy
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were superior to phase SD for discriminating between
normal and abnormal contraction.
However, parameters based on first-order statistics
such as synchrony, entropy, and phase SD do not take
into account the spatial relation between the pixel
values. More advanced statistical parameters can be
used to quantitatively assess ventricular phase.
Approximate entropy (ApEn) is a regularity statistic
developed from Kolmogorov–Sinai entropy by Pincus.11
When applied to RNVG phase images, ApEn is a
statistical measure of dyssynchrony within the ventricle.
ApEn calculates the probability that a series of length m
remains similar within a tolerance r at the next point in
the data series, and unlike entropy, takes into account
the similarity of adjacent data points and thus can
accommodate spatial information more accurately.
ApEn is defined as
ApEn ¼ ðN  mÞ1
XNm
i¼1
ln
cimþ1 rð Þ
cim
 
;
where N is the length of data, m is the sequence length, r
is the tolerance, cimþ1 rð Þ is conditional probability that
when a sequence is within the tolerance then the next
element will also be within tolerance. The pixel values
are considered as a data series. Each group of ‘m’ pixels
will be compared to every other group of ‘m’ pixels
within the ROI, including itself. If the group is within
the tolerance value r, it will be counted. This is carried
out for every group of ‘m’ pixels then repeated with
groups of ‘mþ 1’ to calculate probabilities cim and cimþ1 .
ApEn includes a ‘self match’ of vectors creating a
bias towards regularity. Several publications also sug-
gest that ApEn lacks relative consistency, meaning that
the value of ApEn can ‘flip’ when the input parameters
are varied.12 For this reason, the input parameters (m and
r) must be fixed when comparing datasets. At present,
there is no established m, r or normal range for ApEn
applied to RNVG phase images. The values of m and r
that are used will markedly affect the results, so it is
essential to optimize the input parameters for the data
being considered.
ApEn is well established in other fields including
gait analysis and heart rate variability but has not
previously been widely investigated for assessing ven-
tricular contraction.12–19 Cullen et al. investigated
change in ApEn for serial assessment of 8 patients
receiving Herceptin.20 This work found a significant
change in ejection fraction and ApEn over the course of
treatment, however, further work with a larger patient
group is necessary. While change in ApEn has been
considered, ApEn as a predictive marker has not yet
been investigated.
METHOD
ApEn Optimization
Test data were created to simulate patient phase images
using in-house code written in R 3.6.3 (R Development Core
Team, Vienna, Austria),20,21 allowing m and r to be tested in a
controlled environment. The code allowed the mean and SD in
each radial segment to be altered individually, allowing
abnormal segments to be introduced. Some publications
suggest using a r value which is 0.1-0.2 SD of the dataset
and m = 2,21,22 although no justification for this choice was
found in the literature review. This was used as a starting point
to select the test range. A range of m between 1 and 5, and r
between 0.25 and 21 were tested using the simulated data.
Patient phase images representing normal, LBBB, and MI were
subsequently used to test the results.
There is a value of r where the ApEn calculated from both
normal and abnormal phase images is equal, as demonstrated
in Figure 2. This plot shows an example of the variation in
ApEn values comparing a simulated normal and MI phase
image across a range of tolerances r. This emphasizes the need
for choosing an appropriate value of r for the data. If a lower
value of r is selected then a higher ApEn is normal, while if a
larger value of r is selected a higher ApEn represents abnormal
phase. This is consistent with the work published by Yentes
et al.23 The most important factor in the selection is avoiding
the area where abnormal and normal are equal. This ‘flip’
point, where ApEn cannot discriminate between normal and
abnormal, will vary depending on how abnormal the phase is,
so the range of flip points for the data type must be considered.
After optimization, the final m and r values used were
m = 2, r = 7. These values were also tested across the clinical
range of left ventricle sizes using simulated data, to ensure
consistency with an increase in the number of pixels in the data
series, N. The optimization work carried out with both
simulated and patient data provides confidence that the
selected input values are appropriate.
Data Acquisition
A retrospective study was undertaken to review 193
consecutive female patients (mean age: 54) who had an RNVG
scan at Glasgow Western Infirmary Hospital between 2005 and
2008. All patients included in this study had a baseline RNVG
before receiving cardiotoxic cancer therapy. Each patient had
serial 24-frame gated RNVG scans, acquired at intervals of
approximately 3 months for up to 2 years following the
baseline study, with each patient having between 2 and 9
RNVGs. Patients with a baseline LVEF of \ 55% were
excluded from the study.
In-vivo labeling was performed using intravenous admin-
istration of pyrophosphate 20 minutes prior to injection of
Technetium-99m pertechnetate. The administered dose for
each scan was 800 MBq (21.6 mCi).
Each study was acquired with a Picker 3000XP 3-headed
gamma camera (Picker International, Cleveland Heights, Ohio,
USA) with a low-energy high-resolution collimator. The
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gamma camera was positioned to achieve the best septal
separation and the scan was acquired for 5 million counts using
frame mode acquisition and a matrix size of 64 9 64. The
LVEF was assessed by an experienced operator using Picker
Lightbox software, with a manual dual region technique to
measure the ejection fraction.
For this study only the raw images were available,
therefore the baseline study for all 193 patients was repro-
cessed using MAPS Link medical software. Phase and
amplitude images were created from the first-order Fourier
harmonic. For each baseline study a single left ventricle region
was manually drawn, using the end-diastolic image with
reference to the phase and amplitude images. Sixteen patients
were excluded at this stage (11 patients with gating problems,
which were picked up from the phase image and time-activity
curve, 4 patients with a baseline LVEF below 55%, and 1
patient with a baseline scan below diagnostic quality due to
poor radiopharmaceutical labeling), leaving 177 patients.
Data Analysis
Following each patient’s baseline scan, the LVEF from all
subsequent studies was compared to the baseline to establish
the maximum LVEF drop. The reported LVEF from the
original analysis was used, along with the phase images
created using MAPS Link Medical software. Based on the ESC
guidelines, patients were split by LVEF decline into 2 groups,
those who maintained a normal LVEF and those who had an
LVEF drop of over 10% to below 50%.
In-house software written in R 3.6.3 was used to calculate
ApEn for the baseline scans.24 The software creates a data
series from the pixels in each region of interest within the
phase image, starting from the top left it reads the image from
left to right, then right to left on the line below until it reaches
the bottom, meaning each group of ‘m’ pixels will be adjacent
to each other.
ApEn calculations were carried out on the phase images
of the baseline scans, using input parameters m = 2 and r = 7.
Synchrony, entropy, and phase SD were also included for
comparison.
Statistical Analysis
Shapiro–Wilk’s test was used to check the normality of
the distribution for each parameter. To test multivariate
normality the Henze–Zirkler test was used. Significance testing
was performed for each parameter, using the unpaired t test or
Wilcoxon-signed-rank test, based on the outcome of the
univariate test of normality. Hotelling’s T2 test was used to
determine if there was a significant difference between
multivariate means of the different populations.25
A logistic regression model was fitted in R using all of the
phase parameters and the interaction between ApEn and
baseline LVEF. A second logistic regression model was
created which excluded all of the non-significant variables. A
chi-squared test was used to assess the overall significance of
the logistic regression models. The area under the receiver
operator curve (AUC) and significance was reported for both
models.
Random Forest and Naive-Bayes classifiers were fitted
using all predictors with the caret package in R,26 with 10-fold
cross-validation and 3 repeats. The AUC was calculated for
each classifier.
A P value of \ 0.05 was considered significant for all
tests. All data analysis and statistics were performed in R
3.6.3.21,27,28
RESULTS
Patients were split into 2 groups based on the
change in LVEF during treatment. Group 1 maintained a
normal LVEF ([ 50%) during treatment, and Group 2
had a decline in LVEF of more than 10% to below 50%.
The guidelines would recommend that the treatment for
Group 2 is altered or stopped. There was no significant
difference (P[ 0.05) in age between the two groups.
bFigure 1. Example images showing phase pattern and associ-
ated LV phase histogram for a a normal patient with similar
phase values throughout the ventricles, b an MI patient with
late phase values in the area of an apical MI, c a patient with
left bundle branch block, where there is a gradual change in
phase values across the LV, and d a patient with a large
aneurysm where two distinctly separate segments within the
LV are contracting at different times.
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Figure 2. Simulated data representing phase image for a
normal LV (in red) and for a large MI (in blue), showing the
variation of ApEn with tolerance r, where m = 2. The shaded
area represents the difference in ApEn between the normal and
MI phase image in this example.
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ApEn, phase SD, and age were normally distributed
while synchrony, entropy, and baseline LVEF were not.
Multivariate normality testing for ApEn combined with
baseline LVEF revealed that both groups were normally
distributed.
The results for ApEn, synchrony, entropy, and
phase SD are summarized in Table 1. There was a
significant difference (P\ 0.05) in ApEn and LVEF at
baseline between the groups. The combination of ApEn
and baseline LVEF was also significantly different
between the two groups. The other parameters were not
significant.
A boxplot showing the results of ApEn for the
groups can be seen in Figure 3. Figure 4 demonstrates
how the separation between the groups can be improved
by combining the baseline LVEF with the baseline
ApEn. This plot indicates that patients with a lower
LVEF and higher ApEn at their baseline RNVG (lower
right quadrant) are more likely to have an LVEF drop of
more than 10% to below 50%.
The fitted logistic regression modelling demon-
strated that ApEn, baseline LVEF, and their interaction
were significant predictors for CTRCD. The additional
variables/predictors synchrony, entropy, and phase SD
were not important when ApEn and baseline LVEF are
included in the model. The AUC was 0.81 for logistic
regression model 1 with all predictors and 0.88 for
logistic regression model 2 with only the significant
predictors and the interaction between them. A summary
of the logistic regression results is shown in Table 2.
The AUC values for the classifiers and logistic
regression models are compared in Table 3. Using all
predictors, an AUC of 0.87 was achieved under the
Random Forest classifier and 0.78 under the Naive-
Bayes classifier.
DISCUSSION
The results confirm that at the baseline RNVG,
there was a significant difference in ApEn between the
group with LVEF decline of more than 10% to below
50% (Group 2) and the group that maintained a normal
LVEF throughout treatment. ApEn performed better
than synchrony, entropy, and phase SD for predicting
CTRCD in this dataset.
Improved discrimination between the groups was
achieved by considering the combination of baseline
LVEF and baseline ApEn. The results suggest that
Table 1. Summary of results for each phase parameter
Mean ± SD
Significance test P value
Group 1
Maintained
normal LVEF
Group 2 > 10%
drop to LVEF
below 50%
Number of patients 166 11
Age 55 ± 11 56 ± 15 Wilcoxon-rank-signed 0.799
Synchrony 0.991 ± 0.004 0.989 ± 0.004 Wilcoxon-rank-signed 0.121
Entropy 0.559 ± 0.040 0.584 ± 0.028 Wilcoxon-rank-signed 0.054
ApEn 0.348 ± 0.107 0.418 ± 0.076 Two sample t test 0.014
Phase SD 7.90 ± 1.96 8.91 ± 1.78 Wilcoxon-rank-signed 0.094
Baseline LVEF 73.5 ± 6.1 64.5 ± 6.7 Two sample t test \0.001
(ApEn, baseline LVEF) Hotelling’s T2 \0.001
P = 0.014 
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Figure 3. ApEn for patients calculated from baseline RNVG
phase image, split into two groups based on LVEF decline.
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patients with a lower LVEF and higher ApEn at their
baseline RNVG (lower right quadrant in Figure 4) are at
a higher risk of developing CTRCD during treatment. Of
the patients tested, no one who fell within the top left
quadrant in Figure4 had an LVEF drop to below 50%.
The logistic regression model demonstrated the
interaction between ApEn and baseline LVEF was
significant between the two groups, suggesting that
LVEF combined with ApEn has predictive value at the
baseline scan. There was no improvement to the
performance of the model when synchrony, entropy,
and phase SD were included.
The classifiers performed well, achieving an AUC
of 0.78 with Naive-Bayes and 0.87 with Random Forest.
The Random Forest model and logistic regression model
2 performed best on this dataset. However, these results
should be interpreted with caution due to the small
number of patients who had a significant LVEF decline
during treatment. Further work with additional data for
testing would be desirable.
Published studies using echocardiography have
investigated GLS to assess LV contraction abnormalities
and detect sub-clinical changes before any decline in
LVEF, with several studies demonstrating that a change
in GLS during treatment precedes the drop in
LVEF.29–32 Ali et al.33 found that GLS could detect
subtle LV abnormalities prior to chemotherapy, and was
predictive of cardiac events. They also found a signif-
icant difference in baseline LVEF between the groups.
Despite there being published results using strain to
demonstrate subtle abnormalities before treatment, this
is the first RNVG study investigating ApEn as a
predictive measure.
ApEn has shown to be promising in this patient
cohort and can be calculated quickly without any
additional scanning, dose, or processing time. Patients
with higher ApEn and low LVEF at baseline may be
more susceptible to the cardiotoxic effects of the
therapy. Further improvement could potentially be
Hotelling’s test, p = <0.001
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Figure 4. Baseline LVEF plotted against baseline ApEn for
both groups. The dashed lines represent the mean ApEn and
mean LVEF of the test population.
Table 2. Logistic regression models
Predictor
Logistic regression model 1 Logistic Regression model 2
Coefficient P value Coefficient P value
ApEn - 116.3147 0.044 - 99.1931 0.004
Baseline LVEF - 0.9568 0.014 - 0.8518 0.009
ApEn, baseline LVEF interaction 1.7457 0.040 1.5253 0.033
Synchrony 241.7221 0.455
Entropy 22.0685 0.5356
Phase SD 0.2912 0.7761
Model \0.001 \0.001
Table 3. Comparison of performance for each
model and classifier
AUC
Logistic regression 1 (all predictors) 0.81
Logistic regression 2 (ApEn,
baseline LVEF interaction)
0.88
Random forest (all predictors) 0.87
Naive-Bayes (all predictors) 0.78
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achieved by combining ApEn with other clinical param-
eters and assessing as part of wider texture analysis.
Additional data would be necessary to define a decision
boundary using these parameters to highlight those most
at risk.
Limitations of Study
Of the 177 patients included in this study, only 11
patients had an LVEF decline of more than 10% to
below 50%. Due to this study being retrospective,
limited information was available detailing the treatment
and doses, therefore this study does not discriminate
between different chemotherapy regimes. Although the
initial results are promising, a prospective study would
be desirable to continue this work.
Conclusions
Patients who have a normal LVEF before treatment
may have subtle phase abnormalities which can be
detected at the baseline test. The results of this study
suggest that ApEn combined with the baseline LVEF
could potentially predict which patients are at a higher
risk of developing CTRCD, as measured by LVEF
decline, before treatment commences. If patients who
are at a higher risk of CTRCD can be identified, patient
treatment and monitoring could become more personal-
ized to the individual, helping to achieve the best
outcome for each patient.
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risk of developing CTRCD before cardiotoxic treatment
commences.
Disclosures
No financial conflict of interest.
Open Access
This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use,
sharing, adaptation, distribution and reproduction in any
medium or format, as long as you give appropriate credit to
the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article
are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material
is not included in the article’s Creative Commons licence and
your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Hooning M, Botma A, Aleman BMP, Baaijens MHA, Bartelink H,
Klijn JGM, et al. Long-term risk of cardiovascular disease in 10-
year survivors of breast cancer. JNCI 2007;99:365-75.
2. Doyle J, Neugut A, Jacobson J, Grann V, Hershman D. Che-
motherapy and cardiotoxicity in older breast cancer patients: A
population-based study. J Clin Oncol 2005;23:8597-605.
3. Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA,
Duane FK, et al. Cardiovascular disease incidence after internal
mammary chain irradiation and anthracycline based chemotherapy
for breast cancer. Br J Cancer 2008;119:408-18.
4. Perez I, Alam S, Hernandez G, Sancassani R. Cancer therapy-
related cardiac dysfunction: An overview for the clinician. Clin
Med Insights Cardiol 2019;13:117954681986644. https://doi.org/
10.1177/1179546819866445.
5. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al.
Cardiac dysfunction in the trastuzumab clinical trials experience. J
Clin Oncol 2002;20:1215-21.
6. Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano
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